(Q33783647)

English

AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association (English)

1 reference

Europe PubMed Central

29 July 2017

1 reference

based on heuristic

inferred from title

gastroenterology

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

DiMagno EP

1

1 reference

Europe PubMed Central

29 July 2017

Reber HA

2

1 reference

Europe PubMed Central

29 July 2017

Tempero MA

3

1 reference

Europe PubMed Central

29 July 2017

language of work or name

0 references

publication date

1 December 1999

1 reference

Europe PubMed Central

29 July 2017

Gastroenterology

1 reference

Europe PubMed Central

29 July 2017

117

1 reference

Europe PubMed Central

29 July 2017

1464-1484

1 reference

Europe PubMed Central

29 July 2017

6

1 reference

Europe PubMed Central

29 July 2017

Cancer statistics, 1996.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Increasing incidence of pancreatic cancer among women in Olmsted County, Minnesota, 1940 through 1988

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

The National Cancer Data Base report on pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pancreatitis is a risk factor for pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

The risk of pancreatic cancer following pancreatitis: an association due to confounding?

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Intraductal papillary-mucinous tumors of the pancreas: clinicopathologic features, outcome, and nomenclature. Members of the Pancreas Clinic, and Pancreatic Surgeons of Mayo Clinic.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pancreatic mucinous ductal ectasia and intraductal papillary neoplasms. A single malignant clinicopathologic entity

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Mucinous ductal ectasia of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Diabetes and the Risk of Pancreatic Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Islet amyloid polypeptide in patients with pancreatic cancer and diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

A prospective study of glucose tolerance, insulin, C-peptide, and glucagon responses in patients with pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Increased Risk of Pancreatic Cancer in Melanoma-Prone Kindreds withp16INK4Mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Life-style risk factors for pancreatic cancer in Louisiana: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Dietary habits and past medical history as related to fatal pancreas cancer risk among adventists

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Diet and pancreatic cancer: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Carcinogenicity of mutagenic heterocyclic amines formed during the cooking process.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Dietary fish oil (MaxEPA) enhances pancreatic carcinogenesis in azaserine-treated rats

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Effects of dietary fish oil (MaxEPA) on N-nitrosobis(2-oxopropyl)amine (BOP)-induced pancreatic carcinogenesis in hamsters.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Occupation and pancreatic cancer risk in Louisiana

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Vegetables, fruit, and cancer. I. Epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Vegetables, fruit, and cancer. II. Mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pancreatic cancer. Assessment of prognosis by clinical presentation

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Factors influencing survival after resection for ductal adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

CA 19-9 serum course and prognosis of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Elevated serum levels of tumor marker CA19-9 in acute cholangitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Islet amyloid polypeptide amide causes peripheral insulin resistance in vivo in dogs.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Anorexia following the intrahypothalamic administration of amylin

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Ki-ras oncogene activation in preinvasive pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Identification of K-ras oncogene mutations in the pure pancreatic juice of patients with ductal pancreatic cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Detection of point mutations in the K-ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Analysis of Ki-ras codon 12 mutations in the duodenal juice of patients with pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Long-term follow-up of patients with chronic pancreatitis and K-ras gene mutation detected in pancreatic juice

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Analysis of K-ras oncogene mutations in chronic pancreatitis with ductal hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pancreatic tumors: evaluation with endoscopic US, CT, and MR imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Potentially resectable pancreatic adenocarcinoma: spiral CT assessment with surgical and pathologic correlation

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pancreatic masses with inconclusive findings on spiral CT: is there a role for MRI?

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Endoscopic ultrasound in pancreatic tumor diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Localization of Pancreatic Endocrine Tumors by Endoscopic Ultrasonography

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Endoscopic ultrasonography in diagnosis and staging of pancreatic and biliary tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Endosonography-guided fine-needle aspiration biopsy: diagnostic accuracy and complication assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Diagnosis and staging of pancreatic adenocarcinoma with dynamic computed tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Ultrafast magnetic resonance imaging improves the staging of pancreatic tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Preoperative staging and assessment of resectability of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Laparoscopy in the management of pancreatic cancer: endoscopic cholecystojejunostomy for advanced disease

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Laparoscopic biliary and gastric bypass: a useful adjunct in the treatment of carcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Diagnostic workup of patients with suspected pancreatic carcinoma: the University of California-Los Angeles approach

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost?

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

A preoperative biliary stent is associated with increased complications after pancreatoduodenectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Association of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Radical pancreatectomy for pancreatic cancer in the elderly. Is it safe and justified?

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Curative treatment for pancreatic neoplasms. Radical resection.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

One hundred and forty-five consecutive pancreaticoduodenectomies without mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Gastric emptying and small bowel transit of solid food after pylorus-preserving pancreaticoduodenectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Long-term evaluation of pylorus preservation during pancreaticoduodenectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pylorus-preserving versus standard pancreatico-duodenectomy: an analysis of 110 pancreatic and periampullary carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Aggressive surgery for pancreatic duct cell cancer: feasibility, validity, limitations

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Radical pancreatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

The Effects of Regionalization on Cost and Outcome for One General High-Risk Surgical Procedure

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving?

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Collective review of small carcinomas of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Factors influencing survival after resection of pancreatic cancer. A DNA analysis and a histomorphologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pancreatic Cancer Cell DNA Content Correlates With Long-term Survival After Pancreatoduodenectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Prognostic indicators for survival after resection of pancreatic adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Surgical palliation for pancreatic cancer. The UCLA experience

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Surgical palliation for pancreatic cancer: developments during the past two decades

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Evaluation of palliative surgical procedures in unresectable pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pancreatic carcinoma is associated with delayed gastric emptying

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Palliation of malignant gastric outlet obstruction using an endoscopically placed Wallstent

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Expandable metallic prostheses for malignant obstructions of gastric outlet and proximal small bowel

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Prospective randomized double-blind trial of neurolytic coeliac plexus block in patients with pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Comparison between celiac plexus block and morphine treatment on quality of life in patients with pancreatic cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pain and depression in patients with newly diagnosed pancreas cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Assessment of weight loss, food intake, fat metabolism, malabsorption, and treatment of pancreatic insufficiency in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Fate of oral enzymes in pancreatic insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Chemotherapy for pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Phase II trial of 5-fluorouracil, adriamycin, mitomycin C, and streptozotocin (FAM-S) in pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

5-fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Advanced pancreatic cancer: a phase I-II trial of cisplatin, high-dose cytarabine, and caffeine

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM).

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Chemotherapy prolongs survival in inoperable pancreatic carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Neoadjuvant therapy for unresectable pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

A phase I trial of intravenous bromodeoxyuridine and radiation therapy for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Radiation Therapy Combined with Chemotherapy for Inoperable Pancreatic Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Feasibility study of the treatment of primary unresectable carcinoma of the pancreas with 103Pd brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin-d in advanced measurable pancreatic carcinoma.A gastrointestinal tumor study group report

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Randomized study of 5-FU and CCNU in pancreatic cancer: report of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Treatment of Unresectable Pancreatic Carcinoma with 5-Fluorouracil, Vincristine, and CCNU

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone). The French Associations for Surgical Research

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

An Eastern Cooperative Oncology Group phase II study of single agent DHAD, VP-16, aclacinomycin, or spirogermanium in metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Staging of pancreatic and ampullary carcinoma by endoscopic ultrasonography. Comparison with conventional sonography, computed tomography, and angiography

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Curative treatment for pancreatic neoplasms. Standard resection.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0016-5085(99)70298-2

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33783647&oldid=1629521500"